JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (8): 60-63.doi: 10.6040/j.issn.1671-7554.0.2016.199

Previous Articles     Next Articles

Clinical studies on type 2 diabetic patients treated with sitagliptin

PENG Li1, QIANG Ye2, ZHAO Huichen2, CHEN Shihong3, YAO Weidong1, LIU Yuantao2   

  1. 1. Cadres Ward, Jinan Fourth Peoples Hospital, Jinan 250031, Shandong, China;
    2. Department of Endocrinology, Qingdao Municipal Hospital, Qingdao 266011, Shandong, China;
    3. Department of Endocrinology, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2016-02-29 Online:2016-08-10 Published:2016-08-10

PDF (PC)

379

Abstract: Objective To analyze the factors that affect the efficacy of sitagliptin in the treatment of type 2 diabetic mellitus(T2DM)patients. Methods Clinical data of 86 T2DM patients who treated with sitagliptin during Sept.2012 and June 2014 were collected. According to the levels of fasting C peptide, the patients were divided into two groups: maximum C peptide group(n=12)and minimum C peptide group(n=12). Multiple line regression analysis was performed to analyze the factors that might affect the efficacy of sitagliptin. Results After administration of sitagliptin, there was no significant difference in the decrease of fasting blood glucose(FBG)and 2 h post prandial blood glucose(2h-PBG)between the maximum and minimum C peptide groups(P>0.05). Multiple line regression analysis showed that HbA1c was an independent factor that affected the decrease of FBG; baseline 2h-PBG level was an independent factor that affected the efficacy of sitagliptin on 2h-PBG. Sitagliptin significantly decreased glucose excursion(P<0.05), and reduced episodes of hypoglycemia. Conclusion Sitagliptin decreases both FBG and 2h-PBG. The efficacy of sitagliptin may not entirely depend on C peptide levels. Sitagliptin significantly decreases blood excursion and hypoglycemia.

Key words: Type 2 diabetes mellitus, Sitagliptin, Fasting blood glucose, 2 h post prandial blood glucose

CLC Number: 

  • R574
[1] Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2(non-insulin-dependent)diabetes[J]. Diabetologia, 1986, 29(1): 46-52.
[2] Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells[J]. Endocrinology, 2002, 143(8): 3152-3161.
[3] Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus[J]. Diabetologia, 2005, 48(6): 1168-1172.
[4] 叶潇, 张倩, 曹瑛, 等. 西格列汀与阿卡波糖治疗新诊断2型糖尿病患者的疗效比较[J]. 中国糖尿病杂志, 2012, 8(20): 619-621. YE Xiao, ZHANG Qian, CAO Ying, et al. Comparison of therapeutic effects of sitagliptin versus acarbose for newly-diagnosed T2DM patients[J]. Chin J Diabetes, 2012, 8(20): 619-621.
[5] Giuseppe D, Pietro DR, Elena F, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation[J]. Fund Clin Pharmacol, 2014, 28(2): 221-229
[6] Keiji Y. Efficacy of initial basal-supported oral therapy with sitagliptin in untreated type 2 diabetes[J]. Diabetes Ther, 2013, 4(2): 409-416.
[7] Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes, 2006, 55(6): 1695-1704.
[8] Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats[J]. Diabetes, 2003, 52(3): 741-750.
[9] Yuan GY, Jia J, Zhang CL, et al. Safety and effcacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion(CSII)therapy in patients with newly diagnosed type 2 diabetes[J]. Endocrine Journal, 2014, 61(5): 513-521.
[10] Lu J, Zang J, Li H. Impact of three oral antidiabetic drugs on markers of b-Cell function in patients with type 2 diabetes: A meta-analysis[J]. PLoS One, 8(10): e76713. doi:10.1371/journal.pone.0076713.
[11] Gerald HT. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors[J]. World J Diabetes, 2014, 5(5): 636-650.
[12] Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-1439.
[13] Urd K, Jens JH, Sten M. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-Cell function[J]. Diabetes, 2011, 60(5): 1599-1607.
[14] Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes[J]. BMC Endocr Disord, 2003, 3(1): 3.
[15] Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36)amide in type I diabetic patients[J]. Diabetes Care, 1996, 19(6): 580-586.
[16] Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitorsitagliptinas monotherapy on glycemic control in patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(12): 2632-2637.
[17] Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002, 87(3): 1239-1246.
[18] PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study(PKC-DRS)multicenter randomized clinical trial[J]. Diabetes, 2005, 54(7): 2188-2197.
[1] LI Shuai, WANG Yalin, SUN Zhongwen, ZHU Meijia. Expression changes and mechanism of Nod-like receptor protein 3 inflammasome in the cerebral microvascular endothelial cells in type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 6-11.
[2] LIN Dong, GUAN Qingbo. Association of serum testosterone level and non-alcoholic fatty liver disease in male patients with T2DM [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 33-37.
[3] Muhadasi TUERXUNYIMING, Patamu MOHEMAITI, Tuolanguli MAIMAITIKUERBAN. Association of CDKAL1 rs10946398 C/A polymorphism with type 2 diabetes [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(2): 75-85.
[4] YU Ning, GAO Yanyan, XIAN Yuxin, NIU Jiapeng, LI Li, WANG Jing, CAO Caixia. Effect of exenatide on serum chemerin level and liver fat contents in type 2 diabetes mellitus combined with non-alcoholic fatty liver disease patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 51-55.
[5] LIU Yanxun, LIU Jia, ZHANG Tao, WANG Lu, XUE Fuzhong, WANG Ping. Type 2 diabetes mellitus associated with thyroid nodules: a longitudinal health check-up cohort study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 83-86.
[6] PEI Leilei, SUN Zhonghua, LI Zhe, ZHAO Wenping. Effects of sitagliptin combined with high-dose insulin on type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 39-42.
[7] HU Fangzhi, ZHANG Zhengjun, GENG Houfa, LIANG Qiuhua, SUN Lin. Relationship between microalbuminuria and brain damage in patients with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 43-47.
[8] LI Fang. Association between receptor of advanced glycation end products gene polymorphisms, soluble receptor of advanced glycation end products and susceptibility of type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 57-61.
[9] LI Hanbing, GAO Yanyan, LI Li, CAO Caixia, XIAN Yuxin, WANG Jing, NIU Jiapeng. Effect of lansoprazole and exenatide on gastrin and oxyntomodulin in patients with type 2 diabetes [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 64-68.
[10] ZHANG Nan1, YUAN Zhongshang2, ZHANG Xu1, ZHANG Yikun1, YU Chunxiao1, GAO Ling3, ZHAO Jiajun1, GUAN Qingbo1, GUAN Liying4. Association between serum testosterone and lipid profile in men with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 58-61.
[11] ZHANG Yanling1, ZHANG Xu1, ZHANG Wenwen1, WANG Furong2, YU Chunxiao1, GUAN Qingbo1, YU Guina1, GAO Ling3, ZHAO Jiajun1, XU Jin1. Relationship between serum level of 25-hydroxyvitamin D and fasting blood glucose in healthy adults of Jinan [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(3): 59-63.
[12] GUO Ya-di, GAO Yan-yan, LI Li, SUN Rui-xia, WANG Jing, XIAN Yu-xin. Effects of lansoprazole therapy on the plasma glucose and gastrin in the patients with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 62-66.
[13] LIU Wen-ting1, HU Yi-jun1, CHEN Li2, JIANG Guang-shui1. Quantitative analysis of Clostridium leptum subgroup in patients with chronic periodontitis and type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 100-104.
[14] LI Hai-su, YANG Chong-mei. Therapeutic effect of DPP-4 inhibitor on ulcerative colitis in mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 29-33.
[15] ZHANG Min1, GENG Hou-fa2, SUN Lin2. Quantitative evaluation of brain metabolic changes in patients with acute cerebral infarction and type 2 diabetes mellitus using proton magnetic resonance spectroscopy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 74-77.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd